How much revenue does Gufic Biosciences make?

Gufic Biosciences reported 7.46 billion INR in revenue for fiscal year 2025, down 3.1% from 7.70 billion INR in fiscal year 2024. In Q3 2026 revenue was 2.31 billion INR.

Where does Gufic Biosciences make most of its revenue?

India: 80% of revenue by region in fiscal year 2025, followed by Europe (8%).

What companies are similar to Gufic Biosciences?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include FDC Limited (FDC.NS), Novartis India Limited (NOVARTIND.BO), RPG Life Sciences Limited (RPGLIFE.NS), Unichem Laboratories Limited (UNICHEMLAB.NS).

Gufic Biosciences Limited (GUFICBIO.NS) Stock

About Gufic Biosciences Limited

Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, and South America. The company manufactures APIs and bulk drugs, such as antifungals, anaethetics, immuno suppressants, anginotensin receptor blocker, and intermediates for antifungals. It also manufactu...

At a glance

Gufic Biosciences reported revenue of 7.46 billion INR for fiscal year 2025, down 3.1% from fiscal year 2024, and net income of 696.50 million INR. In Q3 2026 (the quarter ended December 31, 2025) revenue was 2.31 billion INR, up 11.4% from a year before. India was its largest region in fiscal year 2025, with 80% of revenue.

Figures from company filings; latest fiscal year ended March 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.